NCT00908362 - Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

December 31, 2009

Conditions

Smoke-related Lung DiseasesChronic Obstructive Pulmonary Disease

Interventions

DRUG

fluticasone

Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.

DRUG

fluticasone/salmeterol

Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.

DRUG

placebo

Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.

Trial Locations (1)

Dep. of Pneumology, University of Rostock, Rostock